Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
Biotech
AstraZeneca, Daiichi ADC fails to improve breast cancer survival
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Dato-DXd has again failed to improve overall survival in a phase 3 trial.
Nick Paul Taylor
Sep 23, 2024 7:23am
Relay breast cancer data tee up clash with AstraZeneca's Truqap
Sep 9, 2024 7:00am
Labcorp, Quest Diagnostics back PreciseDx's $20.7M series B
Aug 21, 2024 11:00am
Exscientia pays $20M for full control of CDK7 cancer prospect
Jul 18, 2024 10:08am
FDA raises Hologic breast marker safety alert after 71 injuries
May 24, 2024 11:20am
New breast cancer guidelines call for first mammogram at age 40
May 2, 2024 3:15pm